Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

Oncotarget | Novel Prognostic Index to Predict Survival Outcomes in Gastric Cancer Patients

News

February 14, 2023
PRESS RELEASE: On January 31, 2023, researchers from Shimane University and Matsue Red Cross Hospital published a new research paper in Oncotarget, entitled, “Novel inflammation-combined prognostic index to predict survival outcomes in patients with gastric cancer.” continue reading »

Oncotarget | Everolimus Inhibits Angiogenesis and Lymphangiogenesis in TP53 Mutant HNSCC by Downregulating STAT3/HIF-1α/VEGF Pathway

News

February 9, 2023
PRESS RELEASE: On February 2, 2023, a new research paper was published in Oncotarget, entitled, “Everolimus downregulates STAT3/HIF-1α/VEGF pathway to inhibit angiogenesis and lymphangiogenesis in TP53 mutant head and neck squamous cell carcinoma (HNSCC).” continue reading »

Oncotarget | The immunoregulatory protein CD200 as a potentially lucrative yet elusive target for cancer therapy

News

February 7, 2023
PRESS RELEASE: On February 4, 2023, Oncotarget published a new research perspective, entitled, “The immunoregulatory protein CD200 as a potentially lucrative yet elusive target for cancer therapy.” continue reading »

The Importance of CD56 in the Fight Against Multiple Myeloma

Oncotarget

February 2, 2023
In a new Oncotarget editorial, researchers discussed their study on CD56 in multiple myeloma. continue reading »

Oncotarget | Mivavotinib for Relapsed/Refractory B-cell Lymphoma (Updated)

News

February 1, 2023
PRESS RELEASE: On January 26, 2023, a new research paper was published in Oncotarget, entitled, “Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659).” continue reading »